fda glp-1 compounding warning letters september 2025 to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads Telehealth booms on surging GLP-1

The main drawbacks of incretin-based therapies are tolerability and weight loss quality

The development of blood-brain barrier permeable AT 4 receptor agonists and antagonists presents a novel and promising new strategy for the treatment of several of these clinical dysfunctions (174177)

High-dose GHRP-6: Moderate-high risk Why it's concerning: Significant appetite increase (can derail diet) Prolactin elevation (gynecomastia risk in sensitive individuals) Cortisol increase at high doses Water retention When it might be acceptable: Moderate doses (100-200mcg, not 300+mcg) Short-term use (8-12 weeks) If appetite increase isn't problematic Safer alternatives: Ipamorelin (no prolactin/cortisol increase) Lower GHRP-6 doses with careful monitoring Hexarelin: Higher risk than benefits justify Why it's problematic: Rapid desensitization (must cycle frequently) Cortisol and prolactin elevation Heart stress concerns Diminishing returns Limited use cases: Very short cycles (4 weeks maximum) Experienced users only With careful monitoring Better options: Ipamorelin for sustained results GHRP-2 for middle ground Synthetic growth hormone: Highest overall risk Why avoid: Complete shutdown of natural GH production Organ growth (hands, feet, jaw, internal organs) Insulin resistance Expensive Requires PCT (post-cycle therapy) Legal issues in most countries Only justified for: Medical growth hormone deficiency Under physician supervision Replacement doses, not supraphysiological Much safer alternatives: CJC-1295 + Ipamorelin stack Natural peptides that stimulate endogenous GH No shutdown, no PCT needed See peptides vs steroids and peptides vs SARMs for safety comparisons

verify current pricing directly at jrnys.com

In the case of PT-141, a growing body of research and case data supports its safety and effectiveness in male patients, especially those for whom PDE5 inhibitors have failed